PGRMC1 Inhibitors
Progesterone receptor membrane component 1 (PGRMC1) is a widely expressed protein found in various tissues and cell types, including the brain, liver, reproductive organs, and immune cells. Despite its name, PGRMC1 is not solely associated with progesterone signaling; rather, it plays diverse roles in cellular processes such as steroidogenesis, cell proliferation, apoptosis, and intracellular signaling. PGRMC1 is primarily localized to the endoplasmic reticulum (ER) and mitochondrial membranes, where it interacts with a multitude of proteins and modulates their activities. One of the well-characterized functions of PGRMC1 is its involvement in cytochrome P450-mediated steroid biosynthesis in the ER, where it acts as a chaperone protein facilitating the transport of cholesterol to the inner mitochondrial membrane for steroid hormone synthesis.
Inhibition of PGRMC1 can be achieved through various mechanisms targeting its interactions with partner proteins or its subcellular localization. For instance, disruption of PGRMC1's interaction with cytochrome P450 enzymes or other regulatory proteins involved in steroidogenesis can hinder steroid hormone production, leading to downstream effects on cellular processes dependent on these hormones. Additionally, modulating PGRMC1's subcellular localization or stability can also impair its function. Strategies targeting PGRMC1 inhibition may involve the development of small molecules or peptides that interfere with specific protein-protein interactions involving PGRMC1 or disrupt its association with cellular membranes. Furthermore, approaches aimed at downregulating PGRMC1 expression through RNA interference or gene editing techniques could provide effective means of inhibiting its function. Overall, elucidating the mechanisms of PGRMC1 inhibition holds promise for understanding its physiological roles and exploring applications in various disease contexts.
SEE ALSO...
Items 1 to 10 of 11 total
Display:
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
Mifepristone | 84371-65-3 | sc-203134 | 100 mg | $61.00 | 17 | |
RU486 inhibits PGRMC1 indirectly by acting as a progesterone receptor antagonist. By blocking progesterone binding to its receptor, RU486 prevents downstream signaling pathways associated with PGRMC1 activation, thereby modulating PGRMC1 function. | ||||||
C646 | 328968-36-1 | sc-364452 sc-364452A | 10 mg 50 mg | $265.00 $944.00 | 5 | |
C646 is a histone acetyltransferase (HAT) inhibitor that indirectly influences PGRMC1. Through the inhibition of HAT, C646 alters histone acetylation patterns, affecting the chromatin structure and gene expression, ultimately modulating PGRMC1 activity. | ||||||
PD 98059 | 167869-21-8 | sc-3532 sc-3532A | 1 mg 5 mg | $40.00 $92.00 | 212 | |
PD98059 is a MEK inhibitor that indirectly influences PGRMC1 through the mitogen-activated protein kinase (MAPK) pathway. By inhibiting MEK, PD98059 disrupts MAPK signaling, leading to downstream effects on PGRMC1 and influencing its cellular functions. | ||||||
LY 294002 | 154447-36-6 | sc-201426 sc-201426A | 5 mg 25 mg | $123.00 $400.00 | 148 | |
LY294002 is a phosphoinositide 3-kinase (PI3K) inhibitor that indirectly modulates PGRMC1 through the PI3K/AKT pathway. By inhibiting PI3K, LY294002 disrupts downstream AKT signaling, influencing PGRMC1 and its associated cellular processes. | ||||||
AG 1024 | 65678-07-1 | sc-205907 | 1 mg | $107.00 | 22 | |
AG-1024 inhibits PGRMC1 indirectly by targeting the insulin-like growth factor 1 receptor (IGF-1R) signaling pathway. By blocking IGF-1R, AG-1024 disrupts downstream signaling cascades, influencing PGRMC1 and its associated cellular functions. | ||||||
Triciribine | 35943-35-2 | sc-200661 sc-200661A | 1 mg 5 mg | $104.00 $141.00 | 14 | |
Triciribine inhibits PGRMC1 indirectly through the AKT pathway. By blocking AKT phosphorylation, Triciribine disrupts downstream signaling events, affecting PGRMC1 and modulating its cellular functions. | ||||||
SB 203580 | 152121-47-6 | sc-3533 sc-3533A | 1 mg 5 mg | $90.00 $349.00 | 284 | |
SB203580 is a p38 MAPK inhibitor that indirectly modulates PGRMC1 through the p38 MAPK pathway. By inhibiting p38 MAPK, SB203580 disrupts downstream signaling events, influencing PGRMC1 and its associated cellular processes. | ||||||
Wortmannin | 19545-26-7 | sc-3505 sc-3505A sc-3505B | 1 mg 5 mg 20 mg | $67.00 $223.00 $425.00 | 97 | |
Wortmannin is a PI3K inhibitor that indirectly influences PGRMC1 through the PI3K/AKT pathway. By inhibiting PI3K, Wortmannin disrupts downstream AKT signaling, influencing PGRMC1 and its associated cellular processes. | ||||||
GDC-0941 | 957054-30-7 | sc-364498 sc-364498A | 5 mg 10 mg | $188.00 $199.00 | 2 | |
GDC-0941 is a PI3K inhibitor that indirectly modulates PGRMC1 through the PI3K/AKT pathway. By inhibiting PI3K, GDC-0941 disrupts downstream AKT signaling, affecting PGRMC1 and its associated cellular functions. | ||||||
SB 202190 | 152121-30-7 | sc-202334 sc-202334A sc-202334B | 1 mg 5 mg 25 mg | $31.00 $128.00 $454.00 | 45 | |
SB202190 is a p38 MAPK inhibitor that indirectly influences PGRMC1 through the p38 MAPK pathway. By inhibiting p38 MAPK, SB202190 disrupts downstream signaling events, affecting PGRMC1 and modulating its cellular processes. | ||||||